Abstract
BackgroundAs increasing numbers of dengue vaccines and therapeutics are in clinical development, standardized consensus clinical endpoint definitions are urgently needed to assess the efficacy of different interventions with respect to disease severity. We aimed to convene dengue experts representing various sectors and dengue endemic areas to review the literature and propose clinical endpoint definitions for moderate and severe disease based on the framework provided by the WHO 2009 classification.MethodsThe endpoints were first proposed and discussed in a structured expert consultation. After that, the Delphi method was carried out to assess the usefulness, validity and feasibility of the standardized clinical disease endpoints for interventional dengue research.ResultsMost respondents (> 80%) agreed there is a need for both standardized clinical endpoints and operationalization of severe endpoints. Most respondents (67%) felt there is utility for moderate severity endpoints, but cited challenges in their development. Hospitalization as a moderate endpoint of disease severity or measure of public health impact was deemed to be useful by only 47% of respondents, but 89% felt it could bring about supplemental information if carefully contextualized according to data collection setting. Over half of the respondents favored alignment of the standard endpoints with the WHO guidelines (58%), but cautioned that the endpoints could have ramifications for public health practice. In terms of data granularity of the endpoints, there was a slight preference for a categorical vs numeric system (e.g. 1–10) (47% vs 34%), and 74% of respondents suggested validating the endpoints using large prospective data sets.ConclusionThe structured consensus-building process was successful taking into account the history of the debate around potential endpoints for severe dengue. There is clear support for the development of standardized endpoints for interventional clinical research and the need for subsequent validation with prospective data sets. Challenges include the complexity of developing moderate disease research endpoints for dengue.
Highlights
As increasing numbers of dengue vaccines and therapeutics are in clinical development, standardized consensus clinical endpoint definitions are urgently needed to assess the efficacy of different interventions with respect to disease severity
Protection against severe forms of disease has been added to the efficacy portfolio of dengue vaccines, and each developer has crafted their own definition of severe disease based on expert opinion and independent data monitoring committee (IDMC) consensus [1, 4]
The participants of the Overall Approach (OA) panel identified themselves as practicing in the following sectors: 50% from academia, 32% from industry, 26% from public health practice, 29% from clinical practice
Summary
As increasing numbers of dengue vaccines and therapeutics are in clinical development, standardized consensus clinical endpoint definitions are urgently needed to assess the efficacy of different interventions with respect to disease severity. Protection against severe forms of disease has been added to the efficacy portfolio of dengue vaccines, and each developer has crafted their own definition of severe disease based on expert opinion and independent data monitoring committee (IDMC) consensus [1, 4]. This lack of standardization impedes our ability to compare results between dengue clinical trials, and evaluate potential products
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have